Last update 24 May 2025

WT1-W10 peptide vaccine(NEC Corp.)

Overview

Basic Info

Drug Type
Shared antigen vaccine, Synthetic peptide vaccine, Therapeutic vaccine
Synonyms
WT1 W10
Target
WT1
Action
modulators
Mechanism
WT1 modulators(Wilms' Tumour 1 modulators)
Therapeutic Areas
NeoplasmsNervous System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
GlioblastomaMyelodysplastic Syndromes
Inactive Indication
Pancreatic Cancer
Originator Organization
NEC Corp.NEC Corp.
Active Organization
NEC Corp.NEC Corp.Kochi University of TechnologyKochi University of Technology
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with WT1-W10 peptide vaccine(NEC Corp.)
JPRN-UMIN000025452
/ CompletedPhase 1IIT
Phase I clinical study of a WT1-W10 peptide immunotherapy combined with standard treatment against diffuse midline glioma (WT1-TR-DMG). - WT1-W10 immunotherapy against DMG (WT1-TR-DMG)
JPRN-UMIN000026049
/ CompletedNot ApplicableIIT
n exploratory trial of a WT1-W10 immunotherapy against pancreatic cancer in combination with the standard S1 chemotherapy. - n exploratory trial of a WT1-W10 immunotherapy against pancreatic cancer in combination with the standard S1 chemotherapy.
JPRN-UMIN000013742
/ CompletedPhase 2IIT
A phase II study of WT1-W10 peptide vaccine monotherapy for patients with previously-treated advanced Non-Small Cell Lung Cancer - A phase II study of WT1 vaccine for previously-treated NSCLC
100 Clinical Results associated with WT1-W10 peptide vaccine(NEC Corp.)
Login to view more data
100 Translational Medicine associated with WT1-W10 peptide vaccine(NEC Corp.)
Login to view more data
100 Patents (Medical) associated with WT1-W10 peptide vaccine(NEC Corp.)
Login to view more data
100 Deals associated with WT1-W10 peptide vaccine(NEC Corp.)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myelodysplastic SyndromesPhase 2
Japan
NEC Corp.NEC Corp.
11 Sep 2009
GlioblastomaPhase 2-
NEC Corp.NEC Corp.
-
GlioblastomaPhase 2-
Kochi University of TechnologyKochi University of Technology
-
GliomaPhase 1
Japan
--
Pancreatic CancerClinical
Japan
--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free